Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palivizumab for RSV Bronchiolitis in Infants
NCT02442427Phase 3Completed
- Sponsor
- Hamad Medical Corporation
- Start
- Sep 2014
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus bronchiolitis comparing Palivizumab with Placebo (2 arms). Primary endpoint: Readmission to infirmary/observation or hospital or PICU at 3 weeks. Started Sep 2014; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus bronchiolitis
Beyond the preview
Go deeper on NCT02442427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442427.